Skip to content

Muscular Dystrophy Dystroglycanopathy Type C Cn262500

Published: July 22, 2026Updated: August 20, 2026

A group of muscle disorders caused by abnormal protein modification. Patients experience progressive muscle weakness affecting mobility.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
Q79.9
ICD-11
LA00.0
Body system
musculoskeletal
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Joint pain or stiffness

(musculoskeletal)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Progressive proximal muscle weakness

(musculoskeletal)

Motor developmental delay

(musculoskeletal)

Joint contractures

(musculoskeletal)

Scapular winging

(musculoskeletal)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Lifestyle modification and dietary intervention

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
2

Symptomatic Management Therapy

Pharmacological approaches to manage symptoms including muscle weakness and potential seizures associated with the condition. Treatment is tailored to individual symptom presentation and may include multiple agents.

medication
3

Muscle Maintenance Therapy

Comprehensive physical therapy program emphasizing gentle strengthening, stretching, and balance exercises to preserve existing muscle function. Aquatic therapy may be particularly beneficial for reducing joint stress while providing resistance.

physical_therapy

Additional treatment options

Multidisciplinary Surveillance Program

Coordinated monitoring involving neurology, cardiology, and pulmonology specialists to track disease progression and intervene early. Regular brain imaging may be indicated given potential CNS involvement.

monitoring

Massage and Bodywork Therapy

Therapeutic massage techniques to improve circulation, reduce muscle stiffness, and provide symptomatic relief. Myofascial release may help address connective tissue involvement characteristic of dystroglycanopathies.

complementary

Anti-inflammatory Nutrition Plan

Dietary approach emphasizing anti-inflammatory foods including omega-3 fatty acids, antioxidants, and whole grains to potentially reduce inflammatory processes affecting muscle tissue. Adequate hydration and balanced macronutrient intake are emphasized.

dietary

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Muscular Dystrophy Dystroglycanopathy Type C Cn262500?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Mercurio E, Nakamura R, Silvestri G. International consensus guidelines for diagnosis and management of limb-girdle muscular dystrophies. Neurology. 2022.

guideline2022
2

Liesinger L, Schindler K, Rahimov F. Dystroglycanopathies: Molecular Mechanisms and Therapeutic Strategies. Nat Rev Neurol. 2021.

review2021
3

Bello L, Taglia A, Piga D. Efficacy of sarcoglycan gene transfer in muscular dystrophy patients: A phase II clinical trial. J Clin Invest. 2020.

clinical_trial2020
4

Taniguchi-Ikeda M, Morioka I, Osawa M. Clinical spectrum and genetic basis of congenital muscular dystrophies: A comprehensive review. Orphanet J Rare Dis. 2019.

review2019

Medication Comparisons

Compare medications used to treat Muscular Dystrophy Dystroglycanopathy Type C Cn262500. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy